Department of Urology, Mount Sinai School of Medicine, New York, New York, USA.
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):355-60. doi: 10.1016/j.ijrobp.2009.01.078. Epub 2009 Jul 23.
To determine factors that influence local control and systemic relapse in patients undergoing permanent prostate brachytherapy (PPB).
A total of 584 patients receiving PPB alone or PPB with external beam radiation therapy (19.5%) agreed to undergo prostate biopsy (PB) at 2 years postimplantion and yearly if results were positive or if the prostate-specific antigen (PSA) level increased. Short-term hormone therapy was used with 280 (47.9%) patients. Radiation doses were converted to biologically effective doses (BED) (using alpha/beta = 2). Comparisons were made by chi-square analysis and linear regression. Survival was determined by the Kaplan-Meier method.
The median PSA concentration was 7.1 ng/ml, and the median follow-up period was 7.1 years. PB results were positive for 48/584 (8.2%) patients. Positive biopsy results by BED group were as follows: 22/121 (18.2%) patients received a BED of < or =150 Gy; 15/244 (6.1%) patients received >150 to 200 Gy; and 6/193 (3.1%; p < 0.001) patients received >200 Gy. Significant associations of positive PB results by risk group were low-risk group BED (p = 0.019), intermediate-risk group hormone therapy (p = 0.011) and BED (p = 0.040), and high-risk group BED (p = 0.004). Biochemical freedom from failure rate at 7 years was 82.7%. Biochemical freedom from failure rate by PB result was 84.7% for negative results vs. 59.2% for positive results (p < 0.001). Cox regression analysis revealed significant associations with BED (p = 0.038) and PB results (p = 0.002) in low-risk patients, with BED (p = 0.003) in intermediate-risk patients, and with Gleason score (p = 0.006), PSA level (p < 0.001), and PB result (p = 0.038) in high-risk patients. Fifty-three (9.1%) patients died, of which eight deaths were due to prostate cancer. Cause-specific survival was 99.2% for negative PB results vs. 87.6% for positive PB results (p < 0.001).
Higher radiation doses are required to achieve local control following PPB. A BED of >200 Gy with an alpha/beta ratio of 2 yields 96.9% local control rate. Failure to establish local control impacts survival.
确定接受永久性前列腺近距离放射治疗(PPB)的患者局部控制和全身复发的影响因素。
共有 584 名接受单纯 PPB 或 PPB 联合外照射放疗(19.5%)的患者同意在植入后 2 年进行前列腺活检(PB),如果结果阳性或前列腺特异性抗原(PSA)水平升高,则每年进行一次。280 名(47.9%)患者接受短期激素治疗。辐射剂量转换为生物有效剂量(BED)(使用 alpha/beta = 2)。通过卡方分析和线性回归进行比较。通过 Kaplan-Meier 方法确定生存情况。
中位 PSA 浓度为 7.1ng/ml,中位随访时间为 7.1 年。584 名患者中有 48/584(8.2%)名患者的 PB 结果阳性。BED 组阳性活检结果如下:低危组 22/121(18.2%)患者接受的 BED <或=150Gy;中危组 15/244(6.1%)患者接受的 BED 为 150-200Gy;高危组 6/193(3.1%)患者接受的 BED >200Gy(p<0.001)。根据风险组,阳性 PB 结果与低危组 BED(p=0.019)、中危组激素治疗(p=0.011)和 BED(p=0.040)以及高危组 BED(p=0.004)显著相关。7 年时生化无失败率为 82.7%。PB 结果阴性的生化无失败率为 84.7%,阳性的为 59.2%(p<0.001)。Cox 回归分析显示,低危组与 BED(p=0.038)和 PB 结果(p=0.002)、中危组与 BED(p=0.003)、高危组与 Gleason 评分(p=0.006)、PSA 水平(p<0.001)和 PB 结果(p=0.038)显著相关。53 名(9.1%)患者死亡,其中 8 例死于前列腺癌。PB 结果阴性的特异性生存为 99.2%,阳性的为 87.6%(p<0.001)。
PPB 后需要更高的辐射剂量才能实现局部控制。采用 alpha/beta 比为 2 的 200Gy 以上 BED 可获得 96.9%的局部控制率。未能建立局部控制会影响生存。